Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 study)

KYUSHU STUDY GROUP OF CLINICAL CANCER (KSCC)

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background/Aim: The Kyushu Study group of Clinical Cancer (KSCC) conducted phase II trials (KSCC0802 - UMIN000001308) concerning liver resectability after first-line treatment of advanced liver-limited colorectal metastases (CRLM) by a prospective, multi-center study. Patients and Methods: Patients received 6 cycles of mFOLFOX6 with bevacizumab followed by evaluating liver resectability. The primary end-point was liver resection rate. Results: The 40 patients enrolled from September 2008 to August 2010. The median number of administration cycles was 6 (range=1-7). The liver resectability cases were 16/40 (40.0 %) and the number of R0 cases was 10 patients (25.0%). An overall response rate was 30.0% (95% CI=15.2%-44.8%). Median progression-free and overall survival of all patients was 9.7 months and 33.0 months), respectively. Conclusion: mFOLFOX6 with bevacizumab regimen is safe and effective for advanced liver-limited CRLM and might lead to high liver resectability.

Original languageEnglish
Pages (from-to)6655-6662
Number of pages8
JournalAnticancer research
Volume34
Issue number11
Publication statusPublished - Nov 1 2014

Fingerprint

Neoplasm Metastasis
Liver
Bevacizumab
Disease-Free Survival
Neoplasms
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 study). / KYUSHU STUDY GROUP OF CLINICAL CANCER (KSCC).

In: Anticancer research, Vol. 34, No. 11, 01.11.2014, p. 6655-6662.

Research output: Contribution to journalArticle

@article{37397f4720ff4777973daeb8163ca6e6,
title = "Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 study)",
abstract = "Background/Aim: The Kyushu Study group of Clinical Cancer (KSCC) conducted phase II trials (KSCC0802 - UMIN000001308) concerning liver resectability after first-line treatment of advanced liver-limited colorectal metastases (CRLM) by a prospective, multi-center study. Patients and Methods: Patients received 6 cycles of mFOLFOX6 with bevacizumab followed by evaluating liver resectability. The primary end-point was liver resection rate. Results: The 40 patients enrolled from September 2008 to August 2010. The median number of administration cycles was 6 (range=1-7). The liver resectability cases were 16/40 (40.0 {\%}) and the number of R0 cases was 10 patients (25.0{\%}). An overall response rate was 30.0{\%} (95{\%} CI=15.2{\%}-44.8{\%}). Median progression-free and overall survival of all patients was 9.7 months and 33.0 months), respectively. Conclusion: mFOLFOX6 with bevacizumab regimen is safe and effective for advanced liver-limited CRLM and might lead to high liver resectability.",
author = "{KYUSHU STUDY GROUP OF CLINICAL CANCER (KSCC)} and Toru Beppu and Yasunori Emi and Shoji Tokunaga and Eiji Oki and Ken Shirabe and Shinichi Ueno and Shoji Tokunaga and Akira Kabashima and Ikuo Takahashi and Hironori Samura and Susumu Eguchi and Yoshito Akagi and Shoji Natsugoe and Yutaka Ogata and Yoshihiro Kakeji and Hideo Baba and Yoshihiko Maehara",
year = "2014",
month = "11",
day = "1",
language = "English",
volume = "34",
pages = "6655--6662",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "11",

}

TY - JOUR

T1 - Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 study)

AU - KYUSHU STUDY GROUP OF CLINICAL CANCER (KSCC)

AU - Beppu, Toru

AU - Emi, Yasunori

AU - Tokunaga, Shoji

AU - Oki, Eiji

AU - Shirabe, Ken

AU - Ueno, Shinichi

AU - Tokunaga, Shoji

AU - Kabashima, Akira

AU - Takahashi, Ikuo

AU - Samura, Hironori

AU - Eguchi, Susumu

AU - Akagi, Yoshito

AU - Natsugoe, Shoji

AU - Ogata, Yutaka

AU - Kakeji, Yoshihiro

AU - Baba, Hideo

AU - Maehara, Yoshihiko

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Background/Aim: The Kyushu Study group of Clinical Cancer (KSCC) conducted phase II trials (KSCC0802 - UMIN000001308) concerning liver resectability after first-line treatment of advanced liver-limited colorectal metastases (CRLM) by a prospective, multi-center study. Patients and Methods: Patients received 6 cycles of mFOLFOX6 with bevacizumab followed by evaluating liver resectability. The primary end-point was liver resection rate. Results: The 40 patients enrolled from September 2008 to August 2010. The median number of administration cycles was 6 (range=1-7). The liver resectability cases were 16/40 (40.0 %) and the number of R0 cases was 10 patients (25.0%). An overall response rate was 30.0% (95% CI=15.2%-44.8%). Median progression-free and overall survival of all patients was 9.7 months and 33.0 months), respectively. Conclusion: mFOLFOX6 with bevacizumab regimen is safe and effective for advanced liver-limited CRLM and might lead to high liver resectability.

AB - Background/Aim: The Kyushu Study group of Clinical Cancer (KSCC) conducted phase II trials (KSCC0802 - UMIN000001308) concerning liver resectability after first-line treatment of advanced liver-limited colorectal metastases (CRLM) by a prospective, multi-center study. Patients and Methods: Patients received 6 cycles of mFOLFOX6 with bevacizumab followed by evaluating liver resectability. The primary end-point was liver resection rate. Results: The 40 patients enrolled from September 2008 to August 2010. The median number of administration cycles was 6 (range=1-7). The liver resectability cases were 16/40 (40.0 %) and the number of R0 cases was 10 patients (25.0%). An overall response rate was 30.0% (95% CI=15.2%-44.8%). Median progression-free and overall survival of all patients was 9.7 months and 33.0 months), respectively. Conclusion: mFOLFOX6 with bevacizumab regimen is safe and effective for advanced liver-limited CRLM and might lead to high liver resectability.

UR - http://www.scopus.com/inward/record.url?scp=84916231139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916231139&partnerID=8YFLogxK

M3 - Article

C2 - 25368271

AN - SCOPUS:84916231139

VL - 34

SP - 6655

EP - 6662

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 11

ER -